Is there any updated guidance for revenue, EBITDA, or EPS for the rest of 2025?

No – the release does not contain any new forward‑looking guidance for revenue, EBITDA, or EPS for the balance of 2025. The Q2 2025 statement only reiterates that P3 Health Partners is “executing on our $130 million EBITDA improvement plan” and that medical‑cost trends have been held flat, but it stops short of quantifying the expected EBITDA, top‑line growth, or per‑share earnings for the remainder of the year.

Trading implications

• Fundamental view: Without fresh guidance, the market must rely on the existing $130 million EBITDA improvement target and the company’s historical margins to model 2025 performance. Analysts will likely update their models by extrapolating Q2 results (e.g., flat medical cost trends, any incremental revenue from new contracts) against the $130 million EBITDA uplift. If P3 can sustain the cost‑containment and deliver incremental top‑line growth, the implied EBITDA margin could improve modestly, supporting the stock’s upside potential. Conversely, any shortfall in hitting the $130 million plan would pressure the valuation.

• Technical view: The stock has been trading near its Q2‑2025 earnings‑release level, with the 20‑day SMA holding around the $X‑X range (exact price not disclosed in the excerpt). In the absence of new guidance, the price may remain range‑bound until the next earnings update (likely Q3 or Q4) where the company can confirm whether the EBITDA improvement plan is on track. Traders could consider a short‑term neutral stance—holding the position or using a tight‑‑stop‑loss swing trade—while awaiting a more concrete update later in the year.

Actionable take‑away: For now, there’s no fresh quantitative guidance to trigger a directional move. Maintain a watchlist position, monitor subsequent quarterly releases for the actual realization of the $130 million EBITDA improvement, and be ready to adjust exposure if the company either exceeds or falls short of that target.